[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

1-317-615-4559

Email address

clinicaltrials.gov@lilly.com

Condition

Prostate Cancer

Treatment type

Interventional

Investigational product

Abemaciclib

Phase

Phase 2/Phase 3

Sponsor

Eli Lilly and Company

ClinicalTrials.gov identifier

NCT03706365

Study number

I3Y-MC-JPCM

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. Histologically confirmed adenocarcinoma of the prostate.
  2. Metastatic prostate cancer documented by positive bone scan and/or measurable soft tissue metastatic lesions by CT or magnetic resonance imaging (MRI).
  3. Progressive disease at study entry demonstrated during continuous androgen-deprivation therapy (ADT)/post orchiectomy defined as one or more of the following:
  4. PSA progression
  5. Radiographic progression per Response Evaluation Criteria in Solid Tumors (RECIST)1.1 for soft tissue and/or per Prostate Cancer Working Group 3 (PCWG3) for bone, with or without PSA progression
  6. Have adequate organ function.
  7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
Exclusion criteria

  1. Prior therapy with cytochrome P450 (CYP)17 inhibitors.
  2. Prior treatment with abemaciclib or any cyclin-dependent kinase (CDK) 4 & 6 inhibitors.
  3. Prior cytotoxic chemotherapy for metastatic castration resistant prostate cancer (participants treated with docetaxel in the metastatic hormone-sensitive prostate cancer [mHSPC] are eligible). Prior radiopharmaceuticals for prostate cancer, or prior enzalutamide, apalutamide, darolutamide or sipuleucel-T. Participants who had prior radiation or surgery to all target lesions.
  4. Currently enrolled in a clinical study involving an investigational product.
  5. Gastrointestinal disorder affecting the absorption or ability to swallow large pills.
  6. Clinically significant heart disease, active or chronic liver disease, moderate/severe hepatic impairment (Child-Pugh Class B and C).

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site